Inactivated cowpea mosaic virus in combination with OX40 agonist primes potent antitumor immunity in a bilateral melanoma mouse model

EC Koellhoffer, C Mao, V Beiss, L Wang… - Molecular …, 2022 - ACS Publications
Viral immunotherapies are being recognized in cancer treatment, with several currently
approved or undergoing clinical testing. While contemporary approaches have focused on …
被引用次数：14 相关文章
[HTML] nih.gov

[HTML][HTML] Inactivated Cowpea Mosaic Virus in Combination with OX40 Agonist Primes Potent Antitumor Immunity in a Bilateral Melanoma Mouse Model

EC Koellhoffer, C Mao, V Beiss, L Wang… - Molecular …, 2022 - ncbi.nlm.nih.gov
Viral immunotherapies are being recognized in cancer treatment, with several currently
approved or undergoing clinical testing. While contemporary approaches have focused on …

Inactivated Cowpea Mosaic Virus in Combination with OX40 Agonist Primes Potent Antitumor Immunity in a Bilateral Melanoma Mouse Model.

EC Koellhoffer, C Mao, V Beiss, L Wang… - Molecular …, 2022 - europepmc.org
Viral immunotherapies are being recognized in cancer treatment, with several currently
approved or undergoing clinical testing. While contemporary approaches have focused on …

Inactivated Cowpea Mosaic Virus in Combination with OX40 Agonist Primes Potent Antitumor Immunity in a Bilateral Melanoma Mouse Model

EC Koellhoffer, C Mao, V Beiss… - Molecular …, 2022 - pubmed.ncbi.nlm.nih.gov
Viral immunotherapies are being recognized in cancer treatment, with several currently
approved or undergoing clinical testing. While contemporary approaches have focused on …